Evidence map›Paper›PMID 40681997›Full record

ArticleBMC bioinformatics2025

A densely connected framework for cancer subtype classification.

Yu Li, Denggao Zheng, Kaijie Sun, Chi Qin, Yuchen Duan, Qingqing Zhou, Yunxia Yin, Hongxing Kan, Jili Hu

Abstract read
In one paragraph

Article in BMC bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yu LiSchool of Medical Information Engineering, Anhui University of Chinese Medicine, Hefei, China.
Denggao ZhengSchool of Medical Information Engineering, Anhui University of Chinese Medicine, Hefei, China.
Kaijie SunSchool of Medical Information Engineering, Anhui University of Chinese Medicine, Hefei, China.
Chi QinSchool of Medical Information Engineering, Anhui University of Chinese Medicine, Hefei, China.
Yuchen DuanSchool of Medical Information Engineering, Anhui University of Chinese Medicine, Hefei, China.
Qingqing ZhouSchool of Medical Information Engineering, Anhui University of Chinese Medicine, Hefei, China.
Yunxia YinSchool of Medical Information Engineering, Anhui University of Chinese Medicine, Hefei, China.
Hongxing KanSchool of Medical Information Engineering, Anhui University of Chinese Medicine, Hefei, China. ffdkhx@ahtcm.edu.cn.
Jili HuSchool of Medical Information Engineering, Anhui University of Chinese Medicine, Hefei, China. hujili@ahtcm.edu.cn.

Funding

Anhui University of Chinese Medicine Grant no. 2024AH050917National Science Foundation Grant no. GXXT-2023-071The Open Fund of High-level Key Discipline of Basic Theory of TCM of the State Administration of Traditional Chinese Medicine, Anhui University of Chinese Medicine ZYJCLLZD-07
6 · The paper itself

Abstract

backgroundReliable identification of cancer subtypes is crucial for devising personalized treatment strategies. Integrating multi-omics data has proven to be an effective method for analyzing cancer subtypes. By combining molecular information across various layers, a more comprehensive understanding of biological characteristics and disease mechanisms can be achieved.

resultsWe propose DEGCN, a novel deep learning model that integrates a three-channel Variational Autoencoder (VAE) for multi-omics dimensionality reduction and a densely connected Graph Convolutional Network (GCN) for effective subtype classification. DEGCN leverages the complementary strengths of non-linear feature extraction and graph-based relational learning, enabling accurate and robust classification of renal cancer subtypes. Experimental results demonstrate that DEGCN achieves a cross-validated classification accuracy of 97.06% ± 2.04% on renal cancer data, outperforming conventional machine learning algorithms and state-of-the-art deep learning models. Moreover, its generalization ability is validated on breast and gastric cancer datasets from TCGA, with cross-validated classification accuracies of 89.82% ± 2.29% and 88.64% ± 5.24%, respectively, indicating strong cross-cancer predictive performance.

conclusionThe study highlights the outstanding performance of DEGCN in heterogeneous data integration and classification accuracy, demonstrating the model's potential in cancer subtype prediction and its application in guiding clinical treatment.

Indexed as

Computational BiologyDeep LearningNeoplasmsAlgorithmsHumansKidney NeoplasmsMachine LearningCancer subtypesDenseNetKidney cancerMulti-omicsVariational autoencoder

Identifiers

PMID40681997
PMCPMC12273249

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.